Anyone heard from(Camille) lately? Anyone tried calling or emailing? Or are we still running on their "word" on things?
This is why no one believes anything will happen this year. Or ever....
In November 2014, we entered into a Manufacturing Services Agreement with Lonza Ltd. and Lonza Sales Ltd. (hereinafter jointly referred to as “Lonza”), whereby we engaged Lonza to be the manufacturer of our Adva-27a anticancer drug. In June 2015 we received a sample of the pilot manufacturing run for evaluation. Our laboratory analyses showed that, while the sample meets the required biological specifications, the amount of material generated (the “Yield”) by the pilot run was found to be significantly lower than planned. During the course of our discussions concerning the problem of the low Yield, Lonza informed us that they required us to pay them $687,818 prior to moving forward with any activity pertaining to the manufacturing agreement we have with them. We have repeatedly indicated to Lonza that a clear path defining exactly how the extremely low Yield issue would be addressed is imperative prior to us making any payments. As of the date of this report, neither party has changed its position. See “Part I, Item 3 – Legal Proceedings.”
Keeping in mind, none of that is verifiable. Lonza won't comment, no one knows if any of that actually happened. That is a huge amount of money they are requesting. These idiots don't have that. They could have used the money they stole from investors for the patents they sold to themselves to fund this, but no one knows where that patent money went. If this was a billion dollar drug (Adva-27a), or you had actual leadership that believed in the drug, they would spend every cent they had to get it to market. There is no drug, there is no plan. SBFM is their own personal bank, nothing more. At this point, I'd accept them diluting this stock to fund another batch of the drug, at least it shows initiative and belief in the product. According to these scam artists, it's so much better than what's currently out there....why not dilute the stock to fund a new batch, rather than buy Atlas Pharma?
